TD 1473

Drug Profile

TD 1473

Alternative Names: TD-1473

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Theravance Biopharma
  • Class Small molecules
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal disorders; Ulcerative colitis

Most Recent Events

  • 17 Feb 2017 Updated pharmacokinetics and safety data from a phase I trial in Healthy volunteers released by Theravance Biopharma
  • 01 Aug 2016 Theravance Biopharma initiates a phase Ib trial for Ulcerative colitis in USA (NCT02818686)
  • 09 Jun 2016 Pharmacokinetics, pharmacodynamics and safety data from a phase I trial and preclinical studies released by Theravance Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top